Current treatment of heart failure with preserved ejection fraction: Should We add life to the remaining years or add years to the remaining life?

Cardiology Research and Practice

Volumn 1, Issue 1, 2013, Pages

  Li, Jia ^a   Becher, Peter Moritz ^a   Blankenberg, Stefan ^a   Westermann, Dirk ^a  

^a UNIVERSITY HEART CENTER HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 (1 BIPHENYL 4 YLMETHYL 3 ETHOXYCARBONYL 1 BUTYLCARBAMOYL)PROPIONIC ACID; 3 (1 BIPHENYL 4 YLMETHYL 3 ETHOXYCARBONYL 1 BUTYLCARBAMOYL)PROPIONIC ACID PLUS VALSARTAN; AMLODIPINE; ATENOLOL; CANDESARTAN; CARVEDILOL; CHLORTALIDONE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; FUROSEMIDE; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE; IRBESARTAN; ISOSORBIDE DINITRATE; IVABRADINE; METOPROLOL; MINERALOCORTICOID ANTAGONIST; PERINDOPRIL; PLACEBO; RAMIPRIL; RANOLAZINE; RELAXIN; SILDENAFIL; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VALSARTAN; VITAMIN D;

ACUTE HEART FAILURE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); COMORBIDITY; CORONARY ARTERY DISEASE; DIAGNOSTIC TEST; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; EXERCISE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HUMAN; HYPERLIPIDEMIA; LIFE EXTENSION; NONHUMAN; PATHOGENESIS; PHARMACOLOGICAL PROCEDURES; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SURVIVAL RATE; TREATMENT INDICATION;

EID: 84887426518     PISSN: None     EISSN: 20900597     Source Type: Journal    
DOI: 10.1155/2013/130724     Document Type: Review

References (108)

1. Owan T. E., Hodge D. O., Herges R. M., Jacobsen S. J., Roger V. L., Redfield M. M., Trends in prevalence and outcome of heart failure with preserved ejection fraction. The New England Journal of Medicine 2006 355 3 251 259 2-s2.0-33746088001 10.1056/NEJMoa052256 (Pubitemid 44079340)
2. Lam C. S. P., Donal E., Kraigher-Krainer E., Vasan R. S., Epidemiology and clinical course of heart failure with preserved ejection fraction. European Journal of Heart Failure 2011 13 1 18 28 2-s2.0-78650397086 10.1093/eurjhf/ hfq121
3. Brouwers F. P., de Boer R. A., van der Harst P., Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. European Heart Journal 2013 34 19 1424 1431 10.1093/eurheartj/eht066
4. Steinberg B. A., Zhao X., Heidenreich P. A., Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 2012 126 1 65 75 10.1161/CIRCULATIONAHA.111.080770
5. Meta-Analysis Global Group in Chronic Heart Failure, The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. European Heart Journal 2012 33 14 1750 1757 10.1093/eurheartj/ehr254
6. McMurray J. J., Adamopoulos S., Anker S. D., ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal 2012 33 14 1787 1847 10.1093/eurheartj/ehs104
7. Yancy C. W., Jessup M., Bozkurt B., 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation 2013 10.1161/CIR.0b013e31829e8776
8. Chan M. M., Lam C. S., How do patients with heart failure with preserved ejection fraction die? European Journal of Heart Failure 2013 15 6 604 613 10.1093/eurjhf/hft062
9. Borlaug B. A., Paulus W. J., Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. European Heart Journal 2011 32 6 670 679 2-s2.0-79952829685 10.1093/eurheartj/ehq426
10. Becher P. M., Lindner D., Fluschnik N., Blankenberg S., Westermann D., Diagnosing heart failure with preserved ejection fraction. Expert Opinion on Medical Diagnostics 2013 7 5 463 474 10.1517/17530059.2013.825246
11. Zile M. R., Baicu C. F., Gaasch W. H., Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. The New England Journal of Medicine 2004 350 19 1953 2018 2-s2.0-3843094224 10.1056/NEJMoa032566 (Pubitemid 38580198)
12. Vanhecke T. E., Kim R., Raheem S. Z., McCullough P. A., Myocardial ischemia in patients with diastolic dysfunction and heart failure. Current Cardiology Reports 2010 12 3 216 222 2-s2.0-77956362588 10.1007/s11886-010-0101- 1
13. Phan T. T., Abozguia K., Nallur Shivu G., Mahadevan G., Ahmed I., Williams L., Dwivedi G., Patel K., Steendijk P., Ashrafian H., Henning A., Frenneaux M., Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency. Journal of the American College of Cardiology 2009 54 5 402 409 2-s2.0-67650547206 10.1016/j.jacc.2009.05.012
14. Westermann D., Kasner M., Steendijk P., Spillmann F., Riad A., Weitmann K., Hoffmann W., Poller W., Pauschinger M., Schultheiss H.-P., Tschöpe C., Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation 2008 117 16 2051 2060 2-s2.0-42449100055 10.1161/CIRCULATIONAHA.107.716886 (Pubitemid 351572179)
15. González A., López B., Querejeta R., Zubillaga E., Echeverría T., Díez J., Filling pressures and collagen metabolism in hypertensive patients with heart failure and normal ejection fraction. Hypertension 2010 55 6 1418 1424 2-s2.0-77952958509 10.1161/HYPERTENSIONAHA.109. 149112
16. Franssen C., Hamdani N., Ottenheijm C. A., Paulus W. J., Relative importance of titin and collagen for myocardial stiffness in metabolic risk-induced heart failure with preserved ejection fraction. Journal of the American College of Cardiology 2013 61 10 E696 E696 10.1016/S0735-1097(13)60696- 8
17. Díez J., Querejeta R., López B., González A., Larman M., Martínez Ubago J. L., Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002 105 21 2512 2517 2-s2.0-0037188574 10.1161/01.CIR.0000017264.66561.3D (Pubitemid 34568973)
18. Weber K. T., Brilla C. G., Janicki J. S., Myocardial fibrosis: functional significance and regulatory factors. Cardiovascular Research 1993 27 3 341 348 2-s2.0-0027407355 (Pubitemid 23116130)
19. Heymans S., Hirsch E., Anker S. D., Aukrust P., Balligand J.-L., Cohen-Tervaert J. W., Drexler H., Filippatos G., Felix S. B., Gullestad L., Hilfiker-Kleiner D., Janssens S., Latini R., Neubauer G., Paulus W. J., Pieske B., Ponikowski P., Schroen B., Schultheiss H.-P., Tschöpe C., van Bilsen M., Zannad F., McMurray J., Shah A. M., Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure 2009 11 2 119 129 2-s2.0-64549091508 10.1093/eurjhf/hfn043
20. Westermann D., Lindner D., Kasner M., Zietsch C., Savvatis K., Escher F., Schlippenbach J. V., Skurk C., Steendijk P., Riad A., Poller W., Schultheiss H.-P., Tschöpe C., Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circulation 2011 4 1 44 52 2-s2.0-79952260400 10.1161/ CIRCHEARTFAILURE.109.931451
21. Paulus W. J., Tschope C., A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. Journal of the American College of Cardiology 2013 62 4 263 271 10.1016/j.jacc.2013.02.092
22. Borlaug B. A., Melenovsky V., Russell S. D., Kessler K., Pacak K., Becker L. C., Kass D. A., Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation 2006 114 20 2138 2147 2-s2.0-33750995868 10.1161/CIRCULATIONAHA.106.632745 (Pubitemid 44747894)
23. Boonyasirinant T., Rajiah P., Setser R. M., Aortic stiffness is increased in hypertrophic cardiomyopathy with myocardial fibrosis. Novel insights in vascular function from magnetic resonance imaging. Journal of the American College of Cardiology 2009 54 3 255 262 2-s2.0-67649596045 10.1016/j.jacc.2009. 03.060
24. Phan T. T., Shivu G. N., Abozguia K., Davies C., Nassimizadeh M., Jimenez D., Weaver R., Ahmed I., Frenneaux M., Impaired heart rate recovery and chronotropic incompetence in patients with heart failure with preserved ejection fraction. Circulation 2010 3 1 29 34 2-s2.0-76549104730 10.1161/ CIRCHEARTFAILURE.109.877720
25. Wang J., Kurrelmeyer K. M., Torre-Amione G., Nagueh S. F., Systolic and diastolic dyssynchrony in patients with diastolic heart failure and the effect of medical therapy. Journal of the American College of Cardiology 2007 49 1 88 96 2-s2.0-33845902228 10.1016/j.jacc.2006.10.023 (Pubitemid 46026901)
26. Redfield M. M., Jacobsen S. J., Borlaug B. A., Rodeheffer R. J., Kass D. A., Age- and gender-related ventricular-vascular stiffening: a community-based study. Circulation 2005 112 15 2254 2262 2-s2.0-26844512182 10.1161/ CIRCULATIONAHA.105.541078 (Pubitemid 41464567)
27. Lam C. S. P., Roger V. L., Rodeheffer R. J., Bursi F., Borlaug B. A., Ommen S. R., Kass D. A., Redfield M. M., Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation 2007 115 15 1982 1990 2-s2.0-34247201690 10.1161/CIRCULATIONAHA.106.659763 (Pubitemid 46625948)
28. Kitzman D. W., Little W. C., Brubaker P. H., Anderson R. T., Gregory Hundley W., Marburger C. T., Brosnihan B., Morgan T. M., Stewart K. P., Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. Journal of the American Medical Association 2002 288 17 2144 2150 2-s2.0-0037032384 10.1001/jama.288.17.2144 (Pubitemid 35265382)
29. Hogg K., McMurray J., Neurohumoral pathways in heart failure with preserved systolic function. Progress in Cardiovascular Diseases 2005 47 6 357 366 2-s2.0-23944432884 10.1016/j.pcad.2005.02.001 (Pubitemid 41188342)
30. van Heerebeek L., Hamdani N., Falcao-Pires I., Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation 2012 126 7 830 839 10.1161/CIRCULATIONAHA.111.076075
31. van Heerebeek L., Franssen C. P., Hamdani N., Verheugt F. W., Somsen G. A., Paulus W. J., Molecular and cellular basis for diastolic dysfunction. Current Heart Failure Reports 2012 9 4 293 302 10.1007/s11897-012-0109-5
32. Akiyama E., Sugiyama S., Matsuzawa Y., Incremental prognostic significance of peripheral endothelial dysfunction in patients with heart failure with normal left ventricular ejection fraction. Journal of the American College of Cardiology 2012 60 18 1778 1786 10.1016/j.jacc.2012.07.036
33. Lam C. S., Brutsaert D. L., Endothelial dysfunction: a pathophysiologic factor in heart failure with preserved ejection fraction. Journal of the American College of Cardiology 2012 60 18 1787 1789 10.1016/j.jacc.2012.08.004
34. Edelmann F., Stahrenberg R., Gelbrich G., Durstewitz K., Angermann C. E., Düngen H.-D., Scheffold T., Zugck C., Maisch B., Regitz-Zagrosek V., Hasenfu G., Pieske B. M., Wachter R., Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction. Clinical Research in Cardiology 2011 100 9 755 764 2-s2.0-80054723481 10.1007/s00392-011-0305-4
35. Abramov D., He K.-L., Wang J., Burkhoff D., Maurer M. S., The impact of extra cardiac comorbidities on pressure volume relations in heart failure and preserved ejection fraction. Journal of Cardiac Failure 2011 17 7 547 555 2-s2.0-79959568898 10.1016/j.cardfail.2011.03.010
36. Ather S., Chan W., Bozkurt B., Aguilar D., Ramasubbu K., Zachariah A. A., Wehrens X. H. T., Deswal A., Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. Journal of the American College of Cardiology 2012 59 11 998 1005 2-s2.0-84857857236 10.1016/j.jacc.2011.11.040
37. Maeder M. T., Kaye D. M., Heart failure with normal left ventricular ejection fraction. Journal of the American College of Cardiology 2009 53 11 905 918 2-s2.0-61549090009 10.1016/j.jacc.2008.12.007
38. Zile M. R., Gaasch W. H., Anand I. S., Haass M., Little W. C., Miller A. B., Lopez-Sendon J., Teerlink J. R., White M., McMurray J. J., Komajda M., McKelvie R., Ptaszynska A., Hetzel S. J., Massie B. M., Carson P. E., Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction study (I-Preserve) trial. Circulation 2010 121 12 1393 1405 2-s2.0-77950223587 10.1161/CIRCULATIONAHA.109.909614
39. Kitzman D. W., Rich M. W., Age disparities in heart failure research. Journal of the American Medical Association 2010 304 17 1950 1951 2-s2.0-78049370738 10.1001/jama.2010.1592
40. Phan T. T., Shivu G. N., Abozguia K., Gnanadevan M., Ahmed I., Frenneaux M., Left ventricular torsion and strain patterns in heart failure with normal ejection fraction are similar to age-related changes. European Journal of Echocardiography 2009 10 6 793 800 2-s2.0-69049118145 10.1093/ejechocard/jep072
41. Yip G. W. K., Wang M., Wang T., Chan S., Fung J. W. H., Yeung L., Yip T., Lau S.-T., Lau C.-P., Tang M.-O., Yu C.-M., Sanderson J., The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart 2008 94 5 573 580 2-s2.0-42549149364 10.1136/hrt.2007.117978 (Pubitemid 351580128)
42. Davis B. R., Kostis J. B., Simpson L. M., Black H. R., Cushman W. C., Einhorn P. T., Farber M. A., Ford C. E., Levy D., Massie B. M., Nawaz S., Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation 2008 118 22 2259 2267 2-s2.0-57749189570 10.1161/CIRCULATIONAHA.107. 762229
43. Yusuf S., Pfeffer M. A., Swedberg K., Granger C. B., Held P., McMurray J. J. V., Michelson E. L., Olofsson B., Östergren J., Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. The Lancet 2003 362 9386 777 781 2-s2.0-0041408234 10.1016/S0140-6736(03)14285-7 (Pubitemid 37093918)
44. Cleland J. G. F., Tendera M., Adamus J., Freemantle N., Polonski L., Taylor J., The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal 2006 27 19 2338 2345 2-s2.0-33748988737 10.1093/eurheartj/ehl250 (Pubitemid 44453578)
45. Massie B. M., Carson P. E., McMurray J. J., Komajda M., McKelvie R., Zile M. R., Anderson S., Donovan M., Iverson E., Staiger C., Ptaszynska A., Irbesartan in patients with heart failure and preserved ejection fraction. The New England Journal of Medicine 2008 359 23 2456 2467 2-s2.0-57349142933 10.1056/NEJMoa0805450
46. Patel K., Fonarow G. C., Kitzman D. W., Angiotensin receptor blockers and outcomes in real-world older patients with heart failure and preserved ejection fraction: a propensity-matched inception cohort clinical effectiveness study. European Journal of Heart Failure 2012 14 10 1179 1188 10.1093/eurjhf/hfs101
47. Holland D. J., Kumbhani D. J., Ahmed S. H., Marwick T. H., Effects of treatment on exercise tolerance, cardiac function, and mortality in heart failure with preserved ejection fraction: a meta-analysis. Journal of the American College of Cardiology 2011 57 16 1676 1686 2-s2.0-79953850855 10.1016/j.jacc.2010.10.057
48. McMurray J., Renin angiotensin blockade in heart failure with preserved ejection fraction: the signal gets stronger. European Heart Journal 2006 27 19 2257 2259 2-s2.0-33749012266 10.1093/eurheartj/ehl249 (Pubitemid 44453561)
49. Lund L. H., Benson L., Dahlstrom U., Edner M., Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. Journal of The American Medical Association 2012 308 20 2108 2117 10.1001/jama.2012.14785
50. Fang J. C., Heart failure therapy: what should clinicians believe? Journal of The American Medical Association 2012 308 20 2144 2146
51. Mujib M., Patel K., Fonarow G. C., Angiotensin-converting enzyme inhibitors and outcomes in heart failure and preserved ejection fraction. The American Journal of Medicine 2013 126 5 401 410
52. Khalid U., Deswal A., Lack of definitive evidence for the use of renin-angiotensin system antagonists for heart failure with preserved ejection fraction. Evidence-Based Medicine 2013 10.1136/eb-2013-101238
53. Gu J., Noe A., Chandra P., Al-Fayoumi S., Ligueros-Saylan M., Sarangapani R., Maahs S., Ksander G., Rigel D. F., Jeng A. Y., Lin T.-H., Zheng W., Dole W. P., Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). Journal of Clinical Pharmacology 2010 50 4 401 414 2-s2.0-77956817833
54. von Lueder T. G., Sangaralingham S. J., Wang B. H., Renin-Angiotensin blockade combined with natriuretic Peptide system augmentation: novel therapeutic concepts to combat heart failure. Circulation Heart Failure 2013 6 3 594 605
55. Mangiafico S., Costello-Boerrigter L. C., Andersen I. A., Cataliotti A., Burnett J. C. Jr., Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. European Heart Journal 2013 34 12 886 893
56. Solomon S. D., Zile M., Pieske B., The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. The Lancet 2012 380 9851 1387 1395 10.1016/S0140-6736(12)61227-6
57. van Veldhuisen D. J., McMurray J. J., Pharmacological treatment of heart failure with preserved ejection fraction: a glimpse of light at the end of the tunnel? European Journal of Heart Failure 2013 15 1 5 8 10.1093/eurjhf/hfs194
58. Pitt B., Zannad F., Remme W. J., Cody R., Castaigne A., Perez A., Palensky J., Wittes J., The effect of spironolactone on morbidity and mortality in patients with severe heart failure. The New England Journal of Medicine 1999 341 10 709 717 2-s2.0-0033517302 10.1056/NEJM199909023411001 (Pubitemid 29407370)
59. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., Bittman R., Hurley S., Kleiman J., Gatlin M., Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. The New England Journal of Medicine 2003 348 14 1309 1321 2-s2.0-0037417252 10.1056/NEJMoa030207 (Pubitemid 36384098)
60. Zannad F., McMurray J. J. V., Krum H., van Veldhuisen D. J., Swedberg K., Shi H., Vincent J., Pocock S. J., Pitt B., Eplerenone in patients with systolic heart failure and mild symptoms. The New England Journal of Medicine 2011 364 1 11 21 2-s2.0-78650399880 10.1056/NEJMoa1009492
61. Deswal A., Richardson P., Bozkurt B., Mann D. L., Results of the Randomized Aldosterone Antagonism in heart failure with Preserved Ejection Fraction trial (RAAM-PEF). Journal of Cardiac Failure 2011 17 8 634 642 2-s2.0-79960984168 10.1016/j.cardfail.2011.04.007
62. Edelmann F., Wachter R., Schmidt A. G., Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. Journal of The American Medical Association 2013 309 8 781 791 10.1001/jama.2013.905
63. Desai A. S., Lewis E. F., Li R., Solomon S. D., Assmann S. F., Boineau R., Clausell N., Diaz R., Fleg J. L., Gordeev I., McKinlay S., O'Meara E., Shaburishvili T., Pitt B., Pfeffer M. A., Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal 2011 162 6 966 e10 2-s2.0-82555168277 10.1016/j.ahj.2011.09.007
64. Bergström A., Andersson B., Edner M., Nylander E., Persson H., Dahlström U., Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-Echocardiographic study (SWEDIC). European Journal of Heart Failure 2004 6 4 453 461 2-s2.0-1342284053 10.1016/j.ejheart.2004.02.003 (Pubitemid 38746589)
65. Conraads V. M., Metra M., Kamp O., de Keulenaer G. W., Pieske B., Zamorano J., Vardas P. E., Böhm M., dei Cas L., Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. European Journal of Heart Failure 2012 14 2 219 225 2-s2.0-84856203229 10.1093/eurjhf/hfr161
66. van Veldhuisen D. J., Cohen-Solal A., Böhm M., Anker S. D., Babalis D., Roughton M., Coats A. J. S., Poole-Wilson P. A., Flather M. D., Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with Heart Failure). Journal of the American College of Cardiology 2009 53 23 2150 2158 2-s2.0-66149123458 10.1016/j.jacc.2009.02.046
67. Yamamoto K., Origasa H., Hori M., Investigators J. D., Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). European Journal of Heart Failure 2013 15 1 110 118 10.1093/eurjhf/hfs141
68. Aronow W. S., Ahn C., Kronzon I., Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction ≥40% treated with diuretics plus angiotensin-converting enzyme inhibitors. American Journal of Cardiology 1997 80 2 207 209 2-s2.0-0030853984 10.1016/S0002-9149(97)00320-2 (Pubitemid 27329224)
69. Zhou J., Shi H., Zhang J., Lu Y., Fu M., Ge J., Rationale and design of the β -blocker in heart failure with normal left ventricular ejection fraction (β -PRESERVE) study. European Journal of Heart Failure 2010 12 2 181 185 2-s2.0-75149129486 10.1093/eurjhf/hfp193
70. Guazzi M., Vicenzi M., Arena R., Guazzi M. D., Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 2011 124 2 164 174 2-s2.0-79960396933 10.1161/CIRCULATIONAHA.110.983866
71. Guazzi M., Vicenzi M., Arena R., Guazzi M. D., PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: result of a 1-year, prospective, randomized, placebo-controlled study. Circulation 2011 4 1 8 17 2-s2.0-79551580284 10.1161/CIRCHEARTFAILURE.110.944694
72. Redfield M. M., Chen H. H., Borlaug B. A., Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. Journal of The American Medical Association 2013 309 12 1268 1277
73. Kitzman D. W., Understanding results of trials in heart failure with preserved ejection fraction: remembering forgotten lessons and enduring principles. Journal of the American College of Cardiology 2011 57 16 1687 1689 2-s2.0-79953878937 10.1016/j.jacc.2011.01.013
74. Setaro J. F., Zaret B. L., Schulman D. S., Black H. R., Soufer R., Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. American Journal of Cardiology 1990 66 12 981 986 2-s2.0-0025129567 10.1016/0002-9149(90)90937-V (Pubitemid 20360593)
75. Hung M. J., Cherng W. J., Kuo L. T., Wang C. H., Effect of verapamil in elderly patients with left ventricular diastolic dysfunction as a cause of congestive heart failure. International Journal of Clinical Practice 2002 56 1 57 62 2-s2.0-0036156549 (Pubitemid 34100540)
76. Tapp R. J., Sharp A., Stanton A. V., O'Brien E., Chaturvedi N., Poulter N. R., Sever P. S., Thom S. A. M., Hughes A. D., Mayet J., Differential effects of antihypertensive treatment on left ventricular diastolic function: an ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) substudy. Journal of the American College of Cardiology 2010 55 17 1875 1881 2-s2.0-77950904358 10.1016/j.jacc.2009.11.084
77. Ahmed A., Rich M. W., Fleg J. L., Zile M. R., Young J. B., Kitzman D. W., Love T. E., Aronow W. S., Adams K. F. Jr., Gheorghiade M., Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation 2006 114 5 397 403 2-s2.0-33745446787 10.1161/CIRCULATIONAHA.106.628347 (Pubitemid 44264821)
78. Meyer P., White M., Mujib M., Nozza A., Love T. E., Aban I., Young J. B., Wehrmacher W. H., Ahmed A., Digoxin and reduction of heart failure hospitalization in chronic systolic and diastolic heart failure. American Journal of Cardiology 2008 102 12 1681 1686 2-s2.0-57649106630 10.1016/j.amjcard.2008.05.068
79. Kjekshus J., Apetrei E., Barrios V., Böhm M., Cleland J. G. F., Cornel J. H., Dunselman P., Fonseca C., Goudev A., Grande P., Gullestad L., Hjalmarson Å., Hradec J., Jánosi A., Kamenský G., Komajda M., Korewicki J., Kuusi T., Mach F., Mareev V., McMurray J. J. V., Ranjith N., Schaufelberger M., Vanhaecke J., van Veldhuisen D. J., Waagstein F., Wedel H., Wikstrand J., Rosuvastatin in older patients with systolic heart failure. The New England Journal of Medicine 2007 357 22 2248 2261 2-s2.0-36549030340 10.1056/NEJMoa0706201 (Pubitemid 350190755)
80. Fukuta H., Sane D. C., Brucks S., Little W. C., Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 2005 112 3 357 363 2-s2.0-22544443085 10.1161/CIRCULATIONAHA.104.519876 (Pubitemid 41022076)
81. Ouzounian M., Tu J. V., Austin P. C., Chong A., Liu P. P., Lee D. S., Statin therapy and clinical outcomes in heart failure: a propensity-matched analysis. Journal of Cardiac Failure 2009 15 3 241 248 2-s2.0-62949201759 10.1016/j.cardfail.2008.10.026
82. Roik M., Statin therapy in patients with heart failure and preserved left ventricular function. Circulation Journal 2009 73 7 1359 2-s2.0-68149173375 10.1253/circj.CJ-09-0242
83. Tehrani F., Morrissey R., Phan A., Chien C., Schwarz E. R., Statin therapy in patients with diastolic heart failure. Clinical Cardiology 2010 33 4 E1 E5 2-s2.0-77950792962 10.1002/clc.20615
84. Gomez-Garre D., Gonzalez-Rubio M. L., Munoz-Pacheco P., Caro-Vadillo A., Aragoncillo P., Fernandez-Cruz A., Rosuvastatin added to standard heart failure therapy improves cardiac remodelling in heart failure rats with preserved ejection fraction. European Journal of Heart Failure 2010 12 9 903 912 2-s2.0-77955971998 10.1093/eurjhf/hfq101
85. Jacobshagen C., Belardinelli L., Hasenfuss G., Maier L. S., Ranolazine for the treatment of heart failure with preserved ejection fraction: background, aims, and design of the RALI-DHF study. Clinical Cardiology 2011 34 7 426 432 2-s2.0-79960430593 10.1002/clc.20897
86. Lovelock J. D., Monasky M. M., Jeong E.-M., Lardin H. A., Liu H., Patel B. G., Taglieri D. M., Gu L., Kumar P., Pokhrel N., Zeng D., Belardinelli L., Sorescu D., Solaro R. J., Dudley S. C., Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. Circulation Research 2012 110 6 841 850 2-s2.0-84858699667 10.1161/CIRCRESAHA.111.258251
87. Nigwekar S. U., Bhan I., Thadhani R., Nutritional vitamin D in dialysis patients: what to D-iscern? Nephrology Dialysis Transplantation 2011 26 3 764 766 2-s2.0-79952170652 10.1093/ndt/gfq799
88. Forman J. P., Williams J. S., Fisher N. D. L., Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans. Hypertension 2010 55 5 1283 1288 2-s2.0-77951498463 10.1161/HYPERTENSIONAHA.109.148619
89. US National Library of Medicine, Study to investigate the effects of vitamin D administration on plasma renin activity in patients with stable Chronic Heart Failure (VitD-CHF). 2010, http://clinicaltrials.gov/ct2/show/ NCT01092130
90. Becher P. M., Lindner D., Miteva K., Savvatis K., Zietsch C., Schmack B., van Linthout S., Westermann D., Schultheiss H.-P., Tschöpe C., Role of heart rate reduction in the prevention of experimental heart failure: comparison between if-channel blockade and β -receptor blockade. Hypertension 2012 59 5 949 957 2-s2.0-84860218769 10.1161/HYPERTENSIONAHA.111.183913
91. Reil J. C., Hohl M., Reil G. H., Heart rate reduction by If-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction. European Heart Journal 2012 34 36 2839 2849 10.1093/eurheartj/ehs218
92. US National Library of Medicine, If channel blockade with ivabradine in patients with diastolic heart failure. 2008, http://clinicaltrials.gov/ct2/show/ NCT00757055
93. Teerlink J. R., Cotter G., Davison B. A., Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. The Lancet 2013 381 9860 29 39 10.1016/S0140-6736(12) 61855-8
94. Teichman S. L., Unemori E., Teerlink J. R., Cotter G., Metra M., Relaxin: review of biology and potential role in treating heart failure. Current Heart Failure Reports 2010 7 2 75 82 2-s2.0-77954623284 10.1007/s11897-010-0010-z
95. Wilson R. M., de Silva D. S., Sato K., Izumiya Y., Sam F., Effects of fixed-dose isosorbide dinitrate/hydralazine on diastolic function and exercise capacity in hypertension-induced diastolic heart failure. Hypertension 2009 54 3 583 590 2-s2.0-70349263587 10.1161/HYPERTENSIONAHA.109.134932
96. US National Library of Medicine, Vasodilator therapy for heart failure and preserved ejection fraction. 2012, http://clinicaltrials.gov/ct2/show/ NCT01516346
97. Edelmann F., Gelbrich G., Dngen H.-D., Fröhling S., Wachter R., Stahrenberg R., Binder L., Töpper A., Lashki D. J., Schwarz S., Herrmann-Lingen C., Löffler M., Hasenfuss G., Halle M., Pieske B., Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise Training in Diastolic Heart Failure) pilot study. Journal of the American College of Cardiology 2011 58 17 1780 1791 2-s2.0-80054768603 10.1016/j.jacc.2011.06.054
98. Haykowsky M. J., Brubaker P. H., John J. M., Stewart K. P., Morgan T. M., Kitzman D. W., Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction. Journal of the American College of Cardiology 2011 58 3 265 274 2-s2.0-79960039049 10.1016/j.jacc.2011.02.055
99. Kitzman D. W., Brubaker P. H., Herrington D. M., Effect of endurance exercise training on endothelial function and arterial stiffness in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. Journal of the American College of Cardiology 2013 62 7 584 592 10.1016/j.jacc.2013.04.033
100. Fujimoto N., Prasad A., Hastings J. L., Cardiovascular effects of 1 year of progressive endurance exercise training in patients with heart failure with preserved ejection fraction. American Heart Journal 2012 164 6 869 877
101. Keteyian S. J., Exercise training in patients with heart failure and preserved ejection fraction: findings awaiting discovery. Journal of the American College of Cardiology 2013 62 7 10.1016/j.jacc.2013.01.098
102. Kass D. A., Kitzman D. W., Alvarez G. E., The restoration of chronotropic competence in heart failure patients with normal ejection fraction (RESET) study: rationale and design. Journal of Cardiac Failure 2010 16 1 17 24 2-s2.0-73049113456 10.1016/j.cardfail.2009.08.008
103. Olshansky B., Sabbah H. N., Hauptman P. J., Colucci W. S., Parasympathetic nervous system and heart failure pathophysiology and potential implications for therapy. Circulation 2008 118 8 863 871 2-s2.0-53749090260 10.1161/CIRCULATIONAHA.107.760405
104. Georgakopoulos D., Little W. C., Abraham W. T., Weaver F. A., Zile M. R., Chronic baroreflex activation: a potential therapeutic approach to heart failure with preserved ejection fraction. Journal of Cardiac Failure 2011 17 2 167 178 2-s2.0-79551681705 10.1016/j.cardfail.2010.09.004
105. Laurent G., Eicher J. C., Mathe A., Permanent left atrial pacing therapy may improve symptoms in heart failure patients with preserved ejection fraction and atrial dyssynchrony: a pilot study prior to a national clinical research programme. European Journal of Heart Failure 2013 15 1 85 93 10.1093/eurjhf/hfs150
106. Chung E. S., Katra R. P., Ghio S., Bax J., Gerritse B., Hilpisch K., Peterson B. J., Feldman D. S., Abraham W. T., Cardiac resynchronization therapy may benefit patients with left ventricular ejection fraction >35: a PROSPECT trial substudy. European Journal of Heart Failure 2010 12 6 581 587 2-s2.0-77952982958 10.1093/eurjhf/hfq009
107. Penicka M., Kocka V., Herman D., Trakalova H., Herold M., Cardiac resynchronization therapy for the causal treatment of heart failure with preserved ejection fraction: insight from a pressure-volume loop analysis. European Journal of Heart Failure 2010 12 6 634 636 2-s2.0-77953004394 10.1093/eurjhf/hfq068
108. Shah S. J., Gheorghiade M., Heart failure with preserved ejection fraction: treat now by treating comorbidities. Journal of the American Medical Association 2008 300 4 431 433 2-s2.0-47849087223 10.1001/jama.300.4.431 (Pubitemid 352040255)